Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials-Reference-Cited by-同舟云学术

Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials

Published:2019-03-20 Issue:10 Volume:15 Page:2315-2327
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Tran Ngoc Huu¹,Chansinghakul Danaya²,Chong Chia Yin³,Low Chian Yong⁴,Shek Lynette P.⁵,Luong Chan Quang¹,Frago Carina⁶,Wartel T. Anh⁶,Sun Sunny⁷,Skipetrova Anna⁸,Bouckenooghe Alain⁶

Affiliation:

1. Department for Disease Control and Prevention, Pasteur Institute Ho Chi Minh City, Ho Chi Minh City, Vietnam

2. Clinical Sciences, Sanofi Pasteur, Pathumwan, Thailand

3. Infectious Diseases, Department of Pediatrics, KK Women’s and Children’s Hospital, Singapore

4. Department of Infectious Disease, Singapore General Hospital, Singapore

5. Department of Pediatrics, National University of Singapore, Singapore

6. Clinical Sciences and Medical Affairs Departments, Sanofi Pasteur, Singapore

7. Biostatistic and Programming Department, Sanofi, Beijing, China

8. Global Pharmacovigilance, Sanofi Pasteur, Lyon, France

Funder

Sanofi Pasteur

Publisher